On March 3, 2021, Food and Drug Administration (FDA) approved CTTQ’s product Fosaprepitant Dimeglumine for Injection, for the prevention of nausea and vomiting induced by chemotherapy. It is CTTQ’s first freeze-dried product approved by FDA, and this approval is another international market pass for this product after obtaining EU marketing authorization.

 

 

Fosaprepitant Dimeglumine is another NK-1 receptor antagonist after Aprepitant. It is a pro-drug of Aprepitant and is currently clinically used to prevent nausea and vomiting induced by chemotherapy. As it is a powder for intravenous injection, it provides the choice of injection administration with more flexibility and convenience comparing with oral administration of Aprepitant, for some patients with disease-related nausea who cannot accept oral administration. Fosaprepitant Dimeglumine for Injection has favorable efficacy, high safety and wide clinical use. It is CTTQ’s important product in anti-tumor field, and has already been marketed in China in October 2019.

 

The approval of Fosaprepitant Dimeglumine for Injection by FDA is another achievement of CTTQ’s internationalization strategy, demonstrating the determination and ability of CTTQ to enter overseas high-end markets once again. The marketing of this product will further accelerate the process of CTTQ expanding the international market of oncology drugs and pave the way for the establishment of CTTQ international brand and subsequent overseas market promotion of a series of high-end generic drugs.